Risk of Serious Infection With Adalimumab in Hidradenitis Suppurativa Compared With Psoriasis

Allergic DiseasesFurther Publications Immunology

Human papillomavirus infection is associated with increased risk of new-onset hidradenitis suppurativa: a population-based cohort study

J Am Acad Dermatol

Gau SY, Lo SW, Hsu C, Chen SJ, Zuberbier T, Chang HC

doi: 10.1016/j.jaad.2024.10.055

Psoriasis

Drug Survival and Safety of Biosimilars Compared with Originator Adalimumab for Psoriasis: A Multinational Cohort Study

Br J Dermatol

Phan DB, Jourdain H, Descalzo-Gallego MA, González-Quesada A, Zureik M, Rivera-Díaz R, Sahuquillo-Torralba A, Lunt M, Garcia-Doval I, Sbidian E, Warren RB, Yiu ZZN

doi: 10.1093/bjd/ljae454

Psoriatic Arthritis

Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic Arthritis

JAMA Dermatol

Wu A, Zhang A, Guo Y, Liu J, Yang DM, Chada LP, Ogdie A, Reddy SM, Gottlieb AB, Scher JU, Merola JF

doi: 10.1001/jamadermatol.2025.2980

Acne

Risk of New-Onset and Recurrent Depression and Anxiety Among Patients With Hidradenitis Suppurativa

JAMA Dermatol

Holgersen N, Rosenø NAL, Nielsen VW, Hjorthøj C, Nordentoft M, Garg A, Strunk A, Thyssen JP, Nilsson SF, Egeberg A, Thomsen SF

doi: 10.1001/jamadermatol.2025.2298

Further Publications Dermatology

Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials

J Eur Acad Dermatol Venereol

Zouboulis CC, Kyrgidis A, Alavi A, Jemec GBE, Martorell A, Marzano AV, van der Zee HH, Wozniak MB, Martinez AL, Kasparek T, Bachhuber T, Ortmann CE, Lobach I, Thomas N, Ravichandran S, Tzellos T

doi: 10.1111/jdv.20369

Psoriasis

Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for Interchangeability

Adv Ther

Deodhar S, Loganathan S, Kadadanamari Subbarama Reddy R, Ranganna GM, Liu S, Hummel MA, Daniluk S, Hanczewska A, Vekovska K, Zegadlo-Mylik M, Pulka G, -Holz EW

doi: 10.1007/s12325-025-03240-5

Atopic Dermatitis

Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab

JAMA Dermatol

Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY

doi: 10.1001/jamadermatol.2025.1578

Atopic Dermatitis

The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study

J Eur Acad Dermatol Venereol

Kridin K, Abdelghaffar M, Bieber K, Thaci D, Ludwig RJ

doi: 10.1111/jdv.20724

Further Publications Dermatology

Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials

J Eur Acad Dermatol Venereol

Calabrese L, Cartocci A, Rubegni P, French LE, Kendziora B

doi: 10.1111/jdv.20617

Related content

Human papillomavirus infection is associated with increased risk of new-onset hidradenitis suppurativa: a population-based cohort study

Drug Survival and Safety of Biosimilars Compared with Originator Adalimumab for Psoriasis: A Multinational Cohort Study

Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic Arthritis

Risk of New-Onset and Recurrent Depression and Anxiety Among Patients With Hidradenitis Suppurativa

Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials

Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for Interchangeability

Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab

The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study

Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials